NYSEAMERICAN:NBYNovaBay Pharmaceuticals Stock Price, Forecast & News Adding Choose a watchlist: Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat Daily Premium to add more stocks to your watchlist. Adding NovaBay Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Log In and Add $1.37 +0.08 (+6.20 %) (As of 07/16/2020 11:52 AM ET) Add Compare Share Today's Range$1.25Now: $1.37▼$1.4450-Day Range N/A52-Week Range$0.24Now: $1.37▼$1.94Volume53,897 shsAverage Volume3.88 million shsMarket Capitalization$39.47 millionP/E RatioN/ADividend YieldN/ABetaN/A ProfileAnalyst RatingsAdvanced ChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesSEC FilingsSocial Media NovaBay Pharmaceuticals, Inc., a biopharmaceutical company, develops, manufactures, and markets non-antibiotic and anti-infective products for the eye care market in the United States, China, and internationally. It offers Avenova, a prescription product for cleansing and removing foreign materials, including microorganisms and debris from skin around the eye; NeutroPhase for wound care market; CelleRx for the aesthetic dermatology market; Aganocide compounds patented synthetic molecules for use against bacteria, viruses, and fungi; auriclosene irrigation solution for urology; and intelli-Case, a device for soft and rigid gas permeable contact lenses. NovaBay Pharmaceuticals, Inc. has collaboration and license agreement with Virbac to develop auriclosene, a proprietary compound for veterinary markets. The company was formerly known as NovaCal Pharmaceuticals, Inc. and changed its name to NovaBay Pharmaceuticals, Inc. in February 2007. NovaBay Pharmaceuticals, Inc. was incorporated in 2000 and is based in Emeryville, California.Read More Beat the Market (BTM) Rank™ 1.5 Analyst's Opinion Consensus RatingNovaBay Pharmaceuticals has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 1 buy rating, no hold ratings, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $1.10, NovaBay Pharmaceuticals has a potential downside of 19.7% from its current price of $1.37.Amount of Analyst CoverageNovaBay Pharmaceuticals has received no research coverage in the past 90 days. Previous Next 2.7 Community Rank Outperform VotesNovaBay Pharmaceuticals has received 246 “outperform” votes. (Add your “outperform” vote.)Underperform VotesNovaBay Pharmaceuticals has received 217 “underperform” votes. (Add your “underperform” vote.)Community SentimentNovaBay Pharmaceuticals has received 53.13% “outperform” votes from our community.MarketBeat's community ratings are surveys of what our community members think about NovaBay Pharmaceuticals and other stocks. Vote “Outperform” if you believe NBY will outperform the S&P 500 over the long term. Vote “Underperform” if you believe NBY will underperform the S&P 500 over the long term. You may vote once every thirty days. Previous Next 0.0 Dividend Strength Dividend YieldNovaBay Pharmaceuticals does not currently pay a dividend.Dividend GrowthNovaBay Pharmaceuticals does not have a long track record of dividend growth. Previous Next 0.0 Company Ownership Insider Buying vs. Insider SellingIn the past three months, NovaBay Pharmaceuticals insiders have not sold or bought any company stock. Previous Next 0.0 Earnings and Valuation Previous Next Analyst Opinion: 1.5Community Rank: 2.7Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 0.0 5 -4 -3 -2 -1 -Overall Beat the Market Rank™0.84 out of 5 stars Industry, Sector and Symbol Stock Exchange NYSEAMERICAN Industry Biotechnology Sub-IndustryN/A SectorMedical Current SymbolNYSEAMERICAN:NBY Previous Symbol CUSIPN/A CIK1389545 Webnovabay.com Phone+1-510-8998800Debt Debt-to-Equity RatioN/A Current RatioN/A Quick RatioN/APrice-To-Earnings Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/A Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book ValueN/A Price / BookN/AProfitability EPS (Most Recent Fiscal Year)N/A Net IncomeN/A Net MarginsN/A Return on EquityN/A Return on AssetsN/AMiscellaneous Employees70 Outstanding Shares28,811,000Market Cap$39.47 million Next Earnings Date8/5/2020 (Estimated) OptionableNot Optionable AMEX:NBY Rates by TradingView Receive NBY News and Ratings via Email Sign-up to receive the latest news and ratings for NBY and its competitors with MarketBeat's FREE daily newsletter. NovaBay Pharmaceuticals (NYSEAMERICAN:NBY) Frequently Asked Questions Do Wall Street analysts recommend investors buy shares of NovaBay Pharmaceuticals? 1 Wall Street analysts have issued "buy," "hold," and "sell" ratings for NovaBay Pharmaceuticals in the last year. There are currently 1 buy rating for the stock, resulting in a consensus recommendation of "Buy." View analyst ratings for NovaBay Pharmaceuticals. When is NovaBay Pharmaceuticals' next earnings date? NovaBay Pharmaceuticals is scheduled to release its next quarterly earnings announcement on Wednesday, August 5th 2020. View our earnings forecast for NovaBay Pharmaceuticals. How were NovaBay Pharmaceuticals' earnings last quarter? NovaBay Pharmaceuticals, Inc. (NYSEAMERICAN:NBY) issued its earnings results on Thursday, May, 7th. The biopharmaceutical company reported ($0.06) EPS for the quarter, beating the Thomson Reuters' consensus estimate of ($0.07) by $0.01. The biopharmaceutical company earned $1.89 million during the quarter. View NovaBay Pharmaceuticals' earnings history. When did NovaBay Pharmaceuticals' stock split? How did NovaBay Pharmaceuticals' stock split work? NovaBay Pharmaceuticals's stock reverse split on the morning of Monday, December 21st 2015. The 1-25 reverse split was announced on Friday, December 11th 2015. The number of shares owned by shareholders was adjusted after the market closes on Friday, December 18th 2015. An investor that had 100 shares of NovaBay Pharmaceuticals stock prior to the reverse split would have 4 shares after the split. What price target have analysts set for NBY? 1 analysts have issued twelve-month target prices for NovaBay Pharmaceuticals' shares. Their forecasts range from $1.10 to $1.10. On average, they expect NovaBay Pharmaceuticals' share price to reach $1.10 in the next year. This suggests that the stock has a possible downside of 19.7%. View analysts' price targets for NovaBay Pharmaceuticals. Has NovaBay Pharmaceuticals been receiving favorable news coverage? News stories about NBY stock have trended positive recently, according to InfoTrie Sentiment. The research group rates the sentiment of media coverage by analyzing more than six thousand blog and news sources in real time. The firm ranks coverage of companies on a scale of negative five to five, with scores nearest to five being the most favorable. NovaBay Pharmaceuticals earned a media sentiment score of 2.1 on InfoTrie's scale. They also gave media stories about the biopharmaceutical company a news buzz of 10.0 out of 10, indicating that recent media coverage is extremely likely to have an impact on the stock's share price in the near future. View the latest news about NovaBay Pharmaceuticals. Are investors shorting NovaBay Pharmaceuticals? NovaBay Pharmaceuticals saw a increase in short interest during the month of June. As of June 30th, there was short interest totaling 249,000 shares, an increase of 49.4% from the June 15th total of 166,700 shares. Based on an average trading volume of 4,260,000 shares, the days-to-cover ratio is presently 0.1 days. Currently, 1.3% of the company's stock are sold short. View NovaBay Pharmaceuticals' Current Options Chain. Who are some of NovaBay Pharmaceuticals' key competitors? Some companies that are related to NovaBay Pharmaceuticals include Matinas BioPharma (MTNB), Mereo BioPharma Group (MPH), Matinas Biopharma (MTNB), Resverlogix (RVX), Bellus Health (BLU), CorMedix (CRMD), MediGene (MDG1), Monash IVF Group (MVF), AquaBounty Technologies (AQB), Actinium Pharmaceuticals (ATNM), Actinium Pharmaceuticals (ATNM), Imugene (IMU), Orgenesis (ORGS), Orgenesis (ORGS) and BiomX (PHGE). View all competitors. What other stocks do shareholders of NovaBay Pharmaceuticals own? Based on aggregate information from My MarketBeat watchlists, some companies that other NovaBay Pharmaceuticals investors own include Gilead Sciences (GILD), Novavax (NVAX), Inovio Pharmaceuticals (INO), Opko Health (OPK), Biocept (BIOC), Advanced Micro Devices (AMD), CorMedix (CRMD), Exelixis (EXEL), NVIDIA (NVDA) and Arbutus Biopharma (ABUS). Who are NovaBay Pharmaceuticals' key executives? NovaBay Pharmaceuticals' management team includes the following people: Mr. Justin M. Hall, Interim Pres, CEO, Gen. Counsel & Corp. Sec. (Age 41)Mr. Jason Philip Raleigh, Interim CFO, Treasurer & Corp. Controller (Age 42)Dr. David W. Stroman, Sr. VP of Ophthalmic Product Devel. & Chair of Ophthalmology Advisory Board (Age 74) What is NovaBay Pharmaceuticals' stock symbol? NovaBay Pharmaceuticals trades on the New York Stock Exchange (NYSE)AMERICAN under the ticker symbol "NBY." How do I buy shares of NovaBay Pharmaceuticals? Shares of NBY can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. What is NovaBay Pharmaceuticals' stock price today? One share of NBY stock can currently be purchased for approximately $1.37. How big of a company is NovaBay Pharmaceuticals? NovaBay Pharmaceuticals has a market capitalization of $39.47 million. NovaBay Pharmaceuticals employs 70 workers across the globe. What is NovaBay Pharmaceuticals' official website? The official website for NovaBay Pharmaceuticals is novabay.com. How can I contact NovaBay Pharmaceuticals? NovaBay Pharmaceuticals' mailing address is 2000 Powell St Ste 1150, EMERYVILLE, CA 94608-1804, United States. The biopharmaceutical company can be reached via phone at +1-510-8998800. This page was last updated on 7/16/2020 by MarketBeat.com Staff 30 Days of MarketBeat All Access for $1.00 Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your Risk-Free Trial Subscription Here Questions? Get Started with MarketBeat — Read Your Daily NewsletterCheck Out My MarketBeatWatch Our Tutorial VideosAdd a Stock to Your WatchlistSet Up an Instant AlertView a Company's Profile PageView Our Financial CalendarsView Today's Analyst Ratings
